Latest Content

Dr. Patrick J. Hensley shares the treatment landscape of non-muscle-invasive bladder, as well as how individual risk factors can alter treatment options.

Dr. Patrick Wen discussed with CURE how Modeyso treats diffuse midline glioma, and what unmet needs remain for patients now that the therapy is available.

I faced breast cancer and unexpected body changes with resilience and humor, learning to adapt and find strength in the process.

Dr. Alexander Spira explained the difference between a clinical trial and a real-world study in a CURE interview for patients with lung cancer.

Cancer during pregnancy is rare but increasingly recognized as maternal age rises and non-invasive prenatal testing becomes more common.

Ibtrozi may become the new standard for ROS1-mutated lung cancer, with phase 2 data showing safer, longer-lasting benefits for patients.

Urothelial carcinoma, the most common type of bladder cancer, is explained from diagnosis to treatment.

As a metastatic breast cancer patient, I want to control what I can, including my diet and exercise.

This in-depth guide offers a clear look at papillary thyroid cancer, from initial diagnosis and treatment options to long-term prognosis and living well after treatment.

Adrenal cancer is rare, but surgery, medicines, chemotherapy and clinical trials can help patients based on stage, spread and overall health.

Targeted therapies have changed non-small cell lung cancer care, but new side effects, like weight gain, are emerging, says Dr. Lorenzo Belluomini.

Lymphoma is a treatable cancer of the immune system; early diagnosis and personalized treatment with chemo and radiation often lead to a cure.

Dr. Jacob A. Sands shares how patients with lung cancer can interpret clinical trial results and how these findings translate to treatment decisions.